Evaluation Novel Treatment Strategies and Delivery Systems for Age - Related Macular Degeneration and Diabetic Macular Edema Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Ferhina S Ali, MD, MPH 5 4 3 2 1 Russell Spjut, PharmD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Summarize the socioeconomic burden and unmet needs associated with the management of nAMD and DME 5 4 3 2 1 Assess the benefits and limitations of traditional VEGF inhibitors for the treatment of nAMD and DME 5 4 3 2 1 Evaluate the clinical data of newer/emerging treatment options for nAMD and DME 5 4 3 2 1 Examine recent innovations in drug delivery systems for nAMD and DME 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree Which of the following best represents the approximate number of patients affected by AMD and Macular Edema covered by your health plan? 5000 10,000 25,000 50,000 100,000 Other: Which of the following best represents the approximate number of patient lives covered by your health plan? 10,000 100,000 250,000 500,000 1 million Other: Which of the following statements regarding the socioeconomic burden and/or unmet needs associated with the management of AMD/DME is TRUE? Anti-VEGF injections cost Medicare $4.7 billion annually Low patient adherence to anti-VEGF therapies for AMD and DME is typically due to side effects of treatment Rates and frequency of anti-VEGF injections in real-world commercially insured populations remain lower than the number of injections received in clinical trials The estimated annual all-cause cost for patients with nAMD is $50,000 per patient Which of the following is the most common reason for intravitreal anti-VEGF injection non-adherence and non-persistence? Financial burden Advanced age/comorbidities Travel distance Treatment dissatisfaction Please rate your understanding of the benefits and limitations of traditional VEGF inhibitors for the treatment of nAMD and DME. Excellent Very Good Good Fair Poor In the TENAYA and LUCERNE studies, patients treated with faricimab-svoa received a median number of ____ injections over two years, versus 15 injections in patients treated with aflibercept. 8 10 12 14 How does faricimab differ from existing treatment options for AMD and DME? Its exact targets are unknown It only targets one disease pathway It inhibits the VEG-B and MAPK pathways It targets the VEGF-A and Ang-2 pathways How often will you now recommend that clinicians utilize newer anti-VEGF therapies for the management of nAMD and DME? Always Often Sometimes Rarely Never What is the mechanism of action of the ranibizumab port delivery system (PDS)? It provides a continuous release of ranibizumab into the bloodstream It provides a one-time release of ranibizumab into the bloodstream It provides a continuous release of ranibizumab into the vitreous cavity It provides a one-time release of ranibizumab into the vitreous cavity How confident are you now in your ability to examine recent innovations in drug delivery systems for the treatment of nAMD and/or DME? Very Confident Confident Somewhat Confident Not very confident Not at all confident Based on my participation in this activity, I anticipate I will more often: (select all that apply) Recommend treatment strategies which consider the socioeconomic burden of nAMD and DME Recommend treatment strategies which consider unmet needs associated with the management of nAMD and DME Remain apprised of novel strategies for cost-effective and evidence-based AMD and DME care Assess the benefits and limitations of traditional VEGF inhibitors for the treatment of nAMD and DME Assess the burden of intravitreal anti-VEGF injections on patient non-adherence and non-persistence Assess the potential of sustained-release/long-duration treatment options in nAMD and DME Consider the possible positioning of sustained-release/long-duration treatment options for nAMD and DME in clinical practice Remain apprised of the clinical data of newer/emerging treatment options for nAMD and DME Remain apprised of novel methods of drug delivery for nAMD and DME Recommend sustained-release/long-duration treatments for nAMD or DME where appropriate Other (please specify): Please now rate your ability to use currently available therapies to manage nAMD and DME Excellent Very Good Good Fair Poor Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Did you watch Module 1? Yes No Did you watch Module 2? Yes No Did you watch Module 3? Yes No Did you watch Module 4? Yes No
